

Clinical pharmacist's impact in improving therapies safety for patients using oral anticancer agent: A prospective monocentric study

4CPS-288



J. Tabe¹, A. Spinewine¹, V. Ngungu-Yandja², M-E Vryghem², D. Boulet³
¹Université catholique de Louvain (Belgique), Departments of ²Pharmacy and ³Medical Oncology, Centre Hospitalier Régional Mons-Hainaut, Mons (Belgique)



Introduction

Oral anti-cancer agents (OAAs) are frequently used in oncology practice^{1,2}. They allow patients to be cured on an outpatient basis and have an ease of administration that improves their quality of life. OAAs are a source of various medication errors and have numerous drug interactions. Drug interactions involving OAAs are of great concern as they can cause either an altered safety or efficacy profile of cancer treatments.

Objectives

- To determine drug-related problems (DRPs)
- To evaluate the prevalence of potential drug interactions and their clinical impact
- To implement preventive actions to optimize the effectiveness and efficiency of cancer management

Methodology


A prospective interventional study was conducted at the day hospital of the CHR Saint Joseph in Mons (Belgium) over a period of 6 weeks. Data on drugs used for co-morbidities, oral cancer therapies, over-the-counter (OTC) drugs and herbal supplements were collected through a structured patient interview, review of medical records and a call to the dispensing pharmacist. Potential drug interactions involving OAAs were detected during the primary prescribing process using two electronic databases: Lexicomp® Drug Interactions and Micromedex® Healthcare. Two experts (clinical pharmacist and oncologist) assessed the clinical impact according to Hatoum's classification³.

Results

A total of 51 patients were included in the study
The median age of patients included was 70 years

Age (years) (median [P25 ; P75])	70 [63 ; 75]
Total number of drugs (median [P25 ; P75])	7 [4 ; 10]


OAAs	Number	Percentage
Targeted therapy	15	(29,4%)
Immunotherapy	12	(23,5%)
Conventional chemotherapy	11	(21,6%)
Hormonotherapy	9	(17,7%)
Other antitumor agents	4	(7,8%)



Nature of pharmaceutical interventions (n=36)

Nature of the intervention	Number	Percentage
Therapeutic follow-up	19	(54,3%)
Discontinuation of treatment	8	(22,9%)
Optimization of administration modalities	5	(14,3%)
Initiation of treatment	2	(5,7%)
Dosage adjustment	1	(2,8%)
IP acceptance rate		
Accepted	31	(86,1%)
Partially accepted	4	(11,1%)

Drug classes involved in interactions in % (n=26)



Potential deleterious consequences of drug interactions

OAAs	Consequence	Prescribed drug
9	Toxicity ↗	6
8	Efficiency ↘	3

Significant or very significant clinical impact

85,7% → medical specialist
100% → clinical pharmacist

Conclusion

- Drug interactions accounted for the majority of DRPs.
- We identified 26 potentially clinically significant interactions (PCSI) in 24 patients (47%), resulting in the potential increase of toxicity and a risk of ineffectiveness of OAAs and standard therapy. Pharmaceutical interventions led to the discontinuation of treatment in 2 out of 9 cases and the optimization of administration methods in 1 out of 7 cases.
- The clinical pharmacist can improve drug safety by notifying hospital and front-line health care staff of PCSIs to reduce drug therapy problems and optimize drug therapy for these patients.

References

1. Ranchon, F., Bouret, C., Charpiat, B., & Leboucher, G. (2009). Sécurisation de l'emploi des chimiothérapies anticancéreuses administrables par voie orale. *Le Pharmacien Hospitalier*, 44, 36-44.
2. Banna, G. L., Collovà, E., Gebbia, V., Lipari, H., Giuffrida, P., Cavallaro, S., Condorelli, R., Buscarino, C., Tralongo, P., & Ferrau, F. (2010). Anticancer oral therapy: Emerging related issues. *Cancer Treatment Reviews*, 36(8), 595-605.
3. Hatoum, H. T., Hutchinson, R. A., Witte, K. W., & Newby, G. P. (1988). Evaluation of the Contribution of Clinical Pharmacists: Inpatient Care and Cost Reduction. *Drug Intelligence & Clinical Pharmacy*, 22(3), 252-259.

Acknowledgments and contact

I would like to thank Anne Spinewine, Viviane Ngungu-Yandja, Dominique Boulet and all the staff of Department of Medical Oncology.

Contact: jysmine.tabe@epicura.be